AstraZeneca And Daiichi Get Low
A hit with Enhertu in an earlier setting in HER2-low breast cancer patients, and in ultralow expressers, heightens expectations.
A hit with Enhertu in an earlier setting in HER2-low breast cancer patients, and in ultralow expressers, heightens expectations.